Breaking: US FDA’s Bitopertin CRL Shows CNPV Cannot Overcome Surrogate Endpoint Woes

 
• By Bridget Silverman and Sue Sutter
  
Slow down sign
Bitopertin's march to market will be slower now that the FDA denied accelerated approval for the product, which also had a CNPV. (Shutterstock)
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from Complete Response Letters

More from Product Reviews